These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. Fiegl M; Falkner A; Hopfinger G; Brugger S; Zabernigg A; Bauer F; Haslbauer F; Demirtas D; Grossschmidt P; Tatzreiter G; Gastl G; Greil R; Cancer; 2006 Nov; 107(10):2408-16. PubMed ID: 17054106 [TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. Montillo M; Tedeschi A; Miqueleiz S; Veronese S; Cairoli R; Intropido L; Ricci F; Colosimo A; Scarpati B; Montagna M; Nichelatti M; Regazzi M; Morra E J Clin Oncol; 2006 May; 24(15):2337-42. PubMed ID: 16618945 [TBL] [Abstract][Full Text] [Related]
6. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia. Molica S; Montillo M; Ribatti D; Mirabelli R; Tedeschi A; Ricci F; Veronese S; Vacca A; Morra E Haematologica; 2007 Oct; 92(10):1367-74. PubMed ID: 17768114 [TBL] [Abstract][Full Text] [Related]
8. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296 [TBL] [Abstract][Full Text] [Related]
9. Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience. Laurenti L; Piccioni P; Tarnani M; Efremov DG; Fiorini A; Garzia M; Sica S Haematologica; 2005 Aug; 90(8):1143-5. PubMed ID: 16079121 [TBL] [Abstract][Full Text] [Related]
10. Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis. Bezares RF; Stemelin G; Diaz A; Argentieri D; Zubiaur EL; Garay G; Bartomioli M; Ryser R; Milone G Leuk Lymphoma; 2011 Oct; 52(10):1936-41. PubMed ID: 21718136 [TBL] [Abstract][Full Text] [Related]
11. Antibody therapy for chronic lymphocytic leukemia: a promising new modality. Lin TS; Moran M; Lucas M; Waymer S; Jefferson S; Fischer DB; Grever MR; Byrd JC Hematol Oncol Clin North Am; 2004 Aug; 18(4):895-913, ix-x. PubMed ID: 15325705 [TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. Rai KR; Freter CE; Mercier RJ; Cooper MR; Mitchell BS; Stadtmauer EA; Santábarbara P; Wacker B; Brettman L J Clin Oncol; 2002 Sep; 20(18):3891-7. PubMed ID: 12228210 [TBL] [Abstract][Full Text] [Related]
13. The evolving role of alemtuzumab in management of patients with CLL. Faderl S; Coutré S; Byrd JC; Dearden C; Denes A; Dyer MJ; Gregory SA; Gribben JG; Hillmen P; Keating M; Rosen S; Venugopal P; Rai K Leukemia; 2005 Dec; 19(12):2147-52. PubMed ID: 16239912 [TBL] [Abstract][Full Text] [Related]